Patents by Inventor Ippei Yamaoka
Ippei Yamaoka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230263858Abstract: A nutritional formulation for use in suppressing a symptom of refeeding syndrome includes a protein and/or an amino acid in a total amount of 3.5 g or less per 100 kcal. A method for providing nutritional support while suppressing symptoms of refeeding syndrome in patients in an undernutrition state includes the use of the nutritional formulation which includes a protein and/or an amino acid in a total amount of 3.5 g or less per 100 kcal.Type: ApplicationFiled: July 30, 2021Publication date: August 24, 2023Applicant: OTSUKA PHARMACEUTICAL FACTORY, INC.Inventor: Ippei YAMAOKA
-
Patent number: 11155519Abstract: By using ion exchange column chromatography or calcium carbonate to an aqueous solution containing a compound A represented by the following formula and citric acid, citric acid in the aqueous solution is removed and a crystalline compound A is obtained by being thereafter subjected to several steps. Further a high-purity noncrystalline compound A is obtained by using calcium carbonate, sulfuric acid, an organic solvent and the like to the aqueous solution containing the compound A and citric acid to remove citric acid and the crystalline compound A in the solution. The configuration of the crystalline compound A is an SS isomer in the RS notation system. The configuration of the noncrystalline compound A is an SR isomer.Type: GrantFiled: April 23, 2018Date of Patent: October 26, 2021Assignees: OTSUKA PHARMACEUTICAL FACTORY, INC., ADABIO CO., LTD.Inventors: Katsuya Hiraishi, Hiroyuki Soma, Fumie Jimma, Taro Adachi, Ippei Yamaoka, Naoyuki Endo
-
Patent number: 11001573Abstract: Compounds (citric acid derivatives) represented by formulas (1) and (2) below are novel compounds having an inhibitory effect against liver disorder and can be used as liver disorder inhibitors and food additives (wherein R1 represents a C1 to C3 alkyl group optionally having a carboxyl group or a hydroxyl group, and R2 represents a hydrogen atom, or R1 and R2 optionally form a cyclic structure together to represent a C2 to C3 alkylene chain).Type: GrantFiled: October 15, 2019Date of Patent: May 11, 2021Assignees: ADABIO CO., LTD., OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Katsuya Hiraishi, Fumie Jimma, Hiroyuki Soma, Taro Adachi, Masakazu Adachi, Ippei Yamaoka, Tomohiro Kagawa
-
Patent number: 10610558Abstract: The present invention provides a prophylactic and/or therapeutic agent for non-alcoholic fatty liver disease (NAFLD), and particularly non-alcoholic steatohepatitis (NASH) comprising an ume (Japanese apricot) juice concentrate or a processed product thereof. The prophylactic and/or therapeutic agent is obtained by utilizing a component contained in a plant or a processed product thereof, and hence is safe and easily taken. It has been confirmed that when the ume juice concentrate or the processed product thereof is orally administered to a streptozocin (STZ)-induced NAFLD model mouse or an STZ-induced NASH model mouse, liver fibrogenesis can be reduced.Type: GrantFiled: November 25, 2016Date of Patent: April 7, 2020Assignees: ADABIO CO., LTD., OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Katsuya Hiraishi, Fumie Jimma, Hiroyuki Soma, Taro Adachi, Masakazu Adachi, Ippei Yamaoka, Tomohiro Kagawa
-
Publication number: 20200055821Abstract: By using ion exchange column chromatography or calcium carbonate to an aqueous solution containing a compound A represented by the following formula and citric acid, citric acid in the aqueous solution is removed and a crystalline compound A is obtained by being thereafter subjected to several steps. Further a high-purity noncrystalline compound A is obtained by using calcium carbonate, sulfuric acid, an organic solvent and the like to the aqueous solution containing the compound A and citric acid to remove citric acid and the crystalline compound A in the solution. The configuration of the crystalline compound A is an SS isomer in the RS notation system. The configuration of the noncrystalline compound A is an SR isomer.Type: ApplicationFiled: April 23, 2018Publication date: February 20, 2020Applicants: OTSUKA PHARMACEUTICAL FACTORY, INC., ADABIO CO., LTD.Inventors: Katsuya HIRAISHI, Hiroyuki SOMA, Fumie JIMMA, Taro ADACHI, Ippei YAMAOKA, Naoyuki ENDO
-
Publication number: 20200039964Abstract: Compounds (citric acid derivatives) represented by formulas (1) and (2) below are novel compounds having an inhibitory effect against liver disorder and can be used as liver disorder inhibitors and food additives (wherein R1 represents a C1 to C3 alkyl group optionally having a carboxyl group or a hydroxyl group, and R2 represents a hydrogen atom, or R1 and R2 optionally form a cyclic structure together to represent a C2 to C3 alkylene chain).Type: ApplicationFiled: October 15, 2019Publication date: February 6, 2020Applicants: ADABIO CO., LTD., OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Katsuya HIRAISHI, Fumie JIMMA, Hiroyuki SOMA, Taro ADACHI, Masakazu ADACHI, Ippei YAMAOKA, Tomohiro KAGAWA
-
Patent number: 10494362Abstract: Compounds (citric acid derivatives) represented by formulas (1) and (2) below are novel compounds having an inhibitory effect against liver disorder and can be used as liver disorder inhibitors and food additives (wherein R1 represents a C1 to C3 alkyl group optionally having a carboxyl group or a hydroxyl group, and R2 represents a hydrogen atom, or R1 and R2 optionally form a cyclic structure together to represent a C2 to C3 alkylene chain).Type: GrantFiled: November 1, 2016Date of Patent: December 3, 2019Assignees: ADABIO CO., LTD., OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Katsuya Hiraishi, Fumie Jimma, Hiroyuki Soma, Taro Adachi, Masakazu Adachi, Ippei Yamaoka, Tomohiro Kagawa
-
Publication number: 20180334452Abstract: Compounds (citric acid derivatives) represented by formulas (1) and (2) below are novel compounds having an inhibitory effect against liver disorder and can be used as liver disorder inhibitors and food additives (wherein R1 represents a C1 to C3 alkyl group optionally having a carboxyl group or a hydroxyl group, and R2 represents a hydrogen atom, or R1 and R2 optionally form a cyclic structure together to represent a C2 to C3 alkylene chain).Type: ApplicationFiled: November 1, 2016Publication date: November 22, 2018Applicants: ADABIO CO., LTD., OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Katsuya HIRAISHI, Fumie JIMMA, Hiroyuki SOMA, Taro ADACHI, Masakazu ADACHI, Ippei YAMAOKA, Tomohiro KAGAWA
-
Publication number: 20180325975Abstract: The present invention provides a prophylactic and/or therapeutic agent for non-alcoholic fatty liver disease (NAFLD), and particularly non-alcoholic steatohepatitis (NASH) comprising an ume (Japanese apricot) juice concentrate or a processed product thereof. The prophylactic and/or therapeutic agent is obtained by utilizing a component contained in a plant or a processed product thereof, and hence is safe and easily taken. It has been confirmed that when the ume juice concentrate or the processed product thereof is orally administered to a streptozocin (STZ)-induced NAFLD model mouse or an STZ-induced NASH model mouse, liver fibrogenesis can be reduced.Type: ApplicationFiled: November 25, 2016Publication date: November 15, 2018Applicants: ADABIO CO., LTD., OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Katsuya HIRAISHI, Fumie JIMMA, Hiroyuki SOMA, Taro ADACHI, Masakazu ADACHI, Ippei YAMAOKA, Tomohiro KAGAWA
-
Patent number: 8779119Abstract: The invention provides a metal salt of a crosslinked cellulose derivative represented by the following formula (I), wherein the degree of substitution of the hydroxyl group of glucose unit of the crosslinked cellulose derivative by a functional group a is 1 or more. R—O—A??(I) {In the formula (I), R represents a crosslinked cellulose residue and A represents a functional group a having cation-exchange ability.Type: GrantFiled: December 26, 2007Date of Patent: July 15, 2014Assignee: JNC CorporationInventors: Naoyuki Yoshida, Kazushi Ishida, Shuji Sasaki, Ippei Yamaoka
-
Patent number: 8273717Abstract: An inhibitor for perioperative blood sugar elevation characterized by containing a branched amino acid, a compound which can be converted into a branched amino acid in vivo or a compound to which an amino group has been transferred from a branched amino acid. This inhibitor for perioperative blood sugar elevation is useful as a drug which is safe to the living body including human, inhibits abnormal elevation in the blood glucose level caused by anesthesia, surgery, etc., and enables proper blood sugar control, when administered to a perioperative patient.Type: GrantFiled: February 5, 2004Date of Patent: September 25, 2012Assignee: Otsuka Pharmaceutical Factory, Inc.Inventors: Ippei Yamaoka, Yasuhiro Mitsumoto, Masako Doi, Tetsuya Fukunaga, Mitsuo Nakayama
-
Publication number: 20100324280Abstract: The present invention provides a sodium absorption inhibitor, a potassium absorption inhibitor, and a phosphorus absorption inhibitor, and a preventive agent, a therapeutic agent and a food for diseases caused by overconsumption of common salt, potassium and phosphorus or diseases which require restriction of ingestion of common salt, potassium and phosphorus to actively and safely excrete overconsumed common salt, potassium and phosphorus excreted outside the body. R—O-A ??(I) {In the formula (I), R represents a crosslinked cellulose residue and A represents a functional group a having cation-exchange ability.Type: ApplicationFiled: December 26, 2007Publication date: December 23, 2010Applicant: OTSUKA Pharmaceutical Factory, Inc.Inventors: Ippei Yamaoka, Naoyuki Yoshida, Kazushi Ishida, Shuji Sasaki
-
Publication number: 20100317844Abstract: The invention provides a metal salt of a crosslinked cellulose derivative represented by the following formula (I), wherein the degree of substitution of the hydroxyl group of glucose unit of the crosslinked cellulose derivative by a functional group a is 1 or more. R—O-A??(I) {In the formula (I), R represents a crosslinked cellulose residue and A represents a functional group a having cation-exchange ability.Type: ApplicationFiled: December 26, 2007Publication date: December 16, 2010Inventors: Naoyuki Yoshida, Kazushi Ishida, Shuji Sasaki, Ippei Yamaoka
-
Publication number: 20100197787Abstract: Disclosed is a composition for use in the prevention of a hypoglycemic condition, which comprises at least one compound selected from a branched amino acid, a pharmaceutically acceptable salt thereof and a derivative of the amino acid or salt as an active ingredient. The composition can promote the uptake of a saccharide into a brain cell to thereby prevent a hypoglycemic condition.Type: ApplicationFiled: September 29, 2006Publication date: August 5, 2010Inventors: Masako Doi, Ippei Yamaoka
-
Publication number: 20060116426Abstract: An inhibitor for perioperative blood sugar elevation characterized by containing a branched amino acid, a compound which can be converted into a branched amino acid in vivo or a compound to which an amino group has been transferred from a branched amino acid. This inhibitor for perioperative blood sugar elevation is useful as a drug which is safe to the living body including human, inhibits abnormal elevation in the blood glucose level caused by anesthesia, surgery, etc., and enables proper blood sugar control, when administered to a perioperative patient.Type: ApplicationFiled: February 5, 2004Publication date: June 1, 2006Inventors: Ippei Yamaoka, Yasuhiro Mitsumoto, Masako Doi, Tetsuya Fukunaga, Mitsuo Nakayama
-
Publication number: 20050171056Abstract: The present invention provides a sodium ion absorption inhibitor comprising a metal salt, other than a sodium salt, of a cellulose derivatives represented by the following formula (I) as an active ingredient, whereby absorption of salt excessively present into a living body is effectively inhibited and salt excessively present is excreted outside the body positively and safely. Furthermore, the present invention provides an agent for preventing and treating diseases caused by excessive salt ingestion or diseases in which restriction on salt ingestion is required, comprising the same as an active ingredient, and foods comprising the same.Type: ApplicationFiled: April 4, 2005Publication date: August 4, 2005Inventors: Ippei Yamaoka, Kyota Sakai, Kozo Asagi, Takuzi Uesako, Kinzi Hashimoto, Masaru Kobayashi, Tsutomu Uehara
-
Publication number: 20030103931Abstract: An oral agent for adsorbing phosphorus, which comprises a polylysine as an active ingredient; a food which comprises a polylysine; and a method for reducing a phosphorus concentration in blood and a method for excreting phosphorus, using the oral agent for adsorbing phosphorus.Type: ApplicationFiled: July 23, 2002Publication date: June 5, 2003Applicant: CHISSO CORPORATIONInventors: Shinichi Takasaki, Masami Todokoro, Takuji Uesako, Ippei Yamaoka, Masaru Kobayashi
-
Publication number: 20030027789Abstract: The present invention provides a sodium ion absorption inhibitor comprising a metal salt, other than a sodium salt, of a cellulose derivatives represented by the following formula (I) as an active ingredient, whereby absorption of salt excessively present into a living body is effectively inhibited and salt excessively present is excreted outside the body positively and safely. Furthermore, the present invention provides an agent for preventing and treating diseases caused by excessive salt ingestion or diseases in which restriction on salt ingestion is required, comprising the same as an active ingredient, and foods comprising the same.Type: ApplicationFiled: July 12, 2002Publication date: February 6, 2003Inventors: Ippei Yamaoka, Kyota Sakai, Kozo Asagi, Takuzi Uesako, Kinzi Hashimoto, Masaru Kobayashi, Tsutomu Uehara
-
Patent number: 6369043Abstract: An sodium ion absorption inhibitor, a sodium ion excretion accelerator and an agent for preventing and treating a disease caused by excessive common salt ingestion, each of which comprising a metal salt (excluding sodium salt) of lambda-carrageenan as an active ingredient, can excrete excessively ingested common salt outside the body positively and safely, and particularly have excellent action in excreting the sodium ions into feces.Type: GrantFiled: June 26, 2000Date of Patent: April 9, 2002Assignee: Otsuka Pharmaceutical Factory, Inc.Inventors: Takaya Sato, Tutomu Uehara, Ippei Yamaoka, Kozo Asagi, Masaru Kobayashi, Hideaki Kohri